Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug–drug interaction studies

被引：0
|
作者：
Shuying Yang
Misba Beerahee
机构：
[1] GlaxoSmithKline,Clinical Pharmacology Modelling and Simulation, Research & Development
来源：
European Journal of Clinical Pharmacology | 2011年 / 67卷
关键词：
Clinical trial simulation population pharmacokinetic analysis; Drug–drug interaction; Sample size; Power;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 233
页数：8
相关论文
共 50 条
  • [1] Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies
    Yang, Shuying
    Beerahee, Misba
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (03) : 225 - 233
  • [2] Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model
    Chen, Yuan
    Cabalu, Tamara D.
    Callegari, Ernesto
    Einolf, Heidi
    Liu, Lichuan
    Parrott, Neil
    Peters, Sheila Annie
    Schuck, Edgar
    Sharma, Pradeep
    Tracey, Helen
    Upreti, Vijay V.
    Zheng, Ming
    Zhu, Andy Z. X.
    Hall, Stephen D.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (09): : 685 - 695
  • [3] Considerations for Clinical Trial Design and Data Analyses of Thorough QT Studies Using Drug-Drug Interaction
    Zhu, Hao
    Wang, Yaning
    Gobburu, Jogarao V.
    Garnett, Christine E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (10): : 1106 - 1111
  • [4] Population pharmacokinetics - III: Design, analysis, and application of population pharmacokinetic studies
    Ette, EI
    Williams, PJ
    Lane, JR
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (12) : 2136 - 2144
  • [5] Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model
    Kawuma, Aida N. N.
    Wasmann, Roeland E. E.
    Dooley, Kelly E. E.
    Maartens, Gary
    Denti, Paolo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (03) : 1216 - 1221
  • [6] Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction
    Chen, Yuan
    Ma, Fang
    Lu, Tong
    Budha, Nageshwar
    Jin, Jin Yan
    Kenny, Jane R.
    Wong, Harvey
    Hop, Cornelis E. C. A.
    Mao, Jialin
    CLINICAL PHARMACOKINETICS, 2016, 55 (06) : 735 - 749
  • [7] Population pharmacokinetic drug-drug interaction analyses of rufinamide studies in patients with epilepsy
    Fuseau, E
    Critchley, D
    Perdomo, C
    Arroyo, S
    EPILEPSIA, 2005, 46 : 210 - 211
  • [8] Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study
    Kowalski, KG
    Hutmacher, MM
    STATISTICS IN MEDICINE, 2001, 20 (01) : 75 - 91
  • [9] Design of a population pharmacokinetic study using clinical trial simulations: A case study.
    Kowalski, KG
    Hutmacher, MM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 115 - 115
  • [10] Adaptive Optimal Design for Bridging Studies with an Application to Population Pharmacokinetic Studies
    Lee Kien Foo
    Stephen Duffull
    Pharmaceutical Research, 2012, 29 : 1530 - 1543
12345